agents are capable of triggering the immunological process which is manifested clinically as RA. A rational approach to the primary prevention and treatment of the disease will be precluded until all these causes are found. It is therefore necessary to follow up all plausible aetiological clues.
One such clue is the apparent triggering of RA by immunisation. We were intrigued that, in response to a direct question, 19 7 However, attempts to isolate organisms directly from synovium and/ or synovial fluid have, with a few exceptions, been unsuccessful. The preferred explanation is that an infection lights the blue touchpaper of the RA firework and then retires, often without trace.8 If infections can initiate RA then it is certainly plausible that immunisation, whose prime purpose is to mimic the effect of infection on the immune system, will also be capable of triggering RA.
To choose between these explanations the answers to two questions are needed. The first is whether arthritis occurs after immunisation more often than would be expected by chance. The second is whether postimmunisation arthritis is a distinct disease entity. 18 -20 who were immunised against typhoid, tetanus and smallpox. They estimated that 0-3% had adverse reactions occurring 7-10 days after inoculation, the majority of which affected the joints. Both monoarthritis and polyarthritis occurred. Some cases resembled rheumatic fever while others developed a rheumatoid-like arthritis. One man, whose mother had RA, developed severe nodular RA. It is important to remember that increasing refinements have occurred in the preparation of vaccines and the incidence of RF production and adverse reactions in a modern cohort might well be less.
Although such case reports and case series are suggestive of a link between immunisation and arthritis, establishing a causal association requires a comparative group who have not been immunised. There is a dearth of such epidemiological studies. A cautionary tale can be found in the introduction of swine-flu vaccine in the USA. Between 1 October and 16 December 1976, 44 million adults in the USA were immunised with swine flu vaccine. Subsequently over 100 claims were filed against the USA government for various alleged rheumatological adverse reactions including RA. Kurland et al looked at the incidence of RA in the population of Rochester, Minnesota and among army personnel in the few months before and after the immunisation programme and found them to be no different.'8 Using figures from the Mayo clinic'9 they calculated that 1843 cases of RA would have been expected in the whole USA exposed population in the month after immunisation. In fact only 4 were reported to the surveillance centre.
We feel that the NOAR data are sufficiently suggestive to justify the establishment of a prospective study to examine the link between tetanus toxoid administration and the subsequent development of RA. 
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